Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rous

Showing results (471-480 of 480) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 480 results.
Gynecologic Oncology|February 2, 2020
Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based studyCitadel J Cabasag, John Butler, Melina Arnold, et al.
Brain Pathology (Zurich, Switzerland)|April 21, 2020
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and gradingDavid N Louis, Pieter Wesseling, Kenneth Aldape, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Ethnicity & Disease|September 29, 2020
Baseline Characteristics of the 2015-2019 First Year Student Cohorts of the NIH Building Infrastructure Leading to Diversity (BUILD) ProgramKeith C Norris, Heather E McCreath, Karsten Hueffer, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Pageof 48

Showing results (471-480 of 480) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 480 results.
Gynecologic Oncology|February 2, 2020
Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based studyCitadel J Cabasag, John Butler, Melina Arnold, et al.
Brain Pathology (Zurich, Switzerland)|April 21, 2020
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and gradingDavid N Louis, Pieter Wesseling, Kenneth Aldape, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Ethnicity & Disease|September 29, 2020
Baseline Characteristics of the 2015-2019 First Year Student Cohorts of the NIH Building Infrastructure Leading to Diversity (BUILD) ProgramKeith C Norris, Heather E McCreath, Karsten Hueffer, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Pageof 48